Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Press Releases.
Press releases published on July 22, 2025
Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR | Roche, Amgen, and Johnson & Johnson at the Forefront: AnalystView Market Insights
GlobeNewswire
·
July 22, 2025
San Francisco, USA, July 22, 2025 (GLOBE NEWSWIRE) -- The global bispecific antibodies market is witnessing a transformative surge, projected to grow at an impressive compound annual growth rate (CAGR) of 40.10%, reaching a valuation of approximately USD …
Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine
GlobeNewswire
·
July 22, 2025
COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, …
Bavarian Nordics ansøgning om markedsføringstilladelse for chikungunyavaccinen er blevet accepteret til gennemgang af de canadiske lægemiddelmyndigheder
GlobeNewswire
·
July 22, 2025
KØBENHAVN, Danmark, 22. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at de canadiske lægemiddelmyndigheder, Health Canada, har accepteret selskabets ansøgning om markedsføringstilladelse for den virus-lignende partikel (VLP)-baserede, …
Life Biosciences Announces Research Collaboration with SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS) to Expand Pipeline of Cellular Rejuvenation Therapies
GlobeNewswire
·
July 22, 2025
BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- – Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced the signing of a Memorandum of Understanding ( …
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+
GlobeNewswire
·
July 22, 2025
SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type patients, representing 80% of total patients - greatly …
Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
GlobeNewswire
·
July 22, 2025
Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held biotechnology company headquartered in London, UK. The …
Communiqué de presse : Sanofi va acquérir Vicebio et enrichir son pipeline de vaccins respiratoires
GlobeNewswire
·
July 22, 2025
Sanofi va acquérir Vicebio et enrichir son pipeline de vaccins respiratoires Paris, le 22 juillet 2025. Sanofi annonce aujourd'hui la conclusion d'un accord pour l'acquisition de Vicebio Ltd (« Vicebio »), une société de biotechnologie privée dont le siège …